Natixis Advisors L.P. Has $3.63 Million Stake in Catalent, Inc. (NYSE:CTLT)

Natixis Advisors L.P. boosted its holdings in Catalent, Inc. (NYSE:CTLT) by 24.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,307 shares of the company’s stock after purchasing an additional 10,880 shares during the quarter. Natixis Advisors L.P.’s holdings in Catalent were worth $3,634,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of CTLT. FNY Investment Advisers LLC bought a new position in Catalent in the 1st quarter valued at about $34,000. Optiver Holding B.V. bought a new stake in shares of Catalent during the 1st quarter valued at approximately $35,000. Covestor Ltd grew its holdings in shares of Catalent by 84.9% during the 1st quarter. Covestor Ltd now owns 562 shares of the company’s stock valued at $62,000 after purchasing an additional 258 shares during the last quarter. Clearstead Advisors LLC bought a new stake in shares of Catalent during the 1st quarter valued at approximately $48,000. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Catalent during the 1st quarter valued at approximately $48,000.

Catalent Stock Up 2.0 %

Shares of NYSE CTLT opened at $49.97 on Friday. The company has a market capitalization of $9.01 billion, a P/E ratio of 227.15, a price-to-earnings-growth ratio of 5.96 and a beta of 1.23. Catalent, Inc. has a 52-week low of $31.45 and a 52-week high of $99.50. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.34 and a current ratio of 1.84. The company’s 50 day moving average price is $45.77 and its 200-day moving average price is $50.66.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, August 29th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.05 billion. Catalent had a return on equity of 7.13% and a net margin of 0.93%. The firm’s revenue for the quarter was down 15.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.12 EPS. Equities analysts forecast that Catalent, Inc. will post 0.83 earnings per share for the current year.

Insider Transactions at Catalent

In other news, CEO Alessandro Maselli sold 1,485 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $47.13, for a total value of $69,988.05. Following the transaction, the chief executive officer now owns 86,101 shares in the company, valued at approximately $4,057,940.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Alessandro Maselli sold 1,485 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $47.13, for a total transaction of $69,988.05. Following the transaction, the chief executive officer now owns 86,101 shares in the company, valued at approximately $4,057,940.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Steven L. Fasman sold 817 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $44.65, for a total transaction of $36,479.05. Following the transaction, the executive vice president now owns 73,789 shares in the company, valued at approximately $3,294,678.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,442 shares of company stock worth $247,577. Company insiders own 0.58% of the company’s stock.

Analyst Ratings Changes

CTLT has been the topic of several research reports. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Catalent from $37.00 to $45.00 and gave the company a “hold” rating in a report on Tuesday, August 15th. UBS Group lifted their price target on shares of Catalent from $55.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday. TheStreet lowered shares of Catalent from a “c” rating to a “d+” rating in a report on Monday, June 12th. Robert W. Baird lifted their price target on shares of Catalent from $35.00 to $47.00 in a report on Tuesday, June 13th. Finally, Morgan Stanley boosted their target price on shares of Catalent from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $59.42.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.